Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paula F. Carneiro is active.

Publication


Featured researches published by Paula F. Carneiro.


Bioorganic & Medicinal Chemistry | 2012

1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.

Kelly C. G. de Moura; Paula F. Carneiro; Maria do Carmo F. R. Pinto; José A. da Silva; V. R. S. Malta; Carlos A. de Simone; Gleiston G. Dias; Guilherme A. M. Jardim; Jéssica Cantos; Tatiane S. Coelho; Pedro Eduardo Almeida da Silva; Eufrânio N. da Silva

Twenty-three naphthoimidazoles and six naphthoxazoles were synthesised and evaluated against susceptible and rifampicin- and isoniazid-resistant strains of Mycobacterium tuberculosis. Among all the compounds evaluated, fourteen presented MIC values in the range of 0.78 to 6.25 μg/mL against susceptible and resistant strains of M. tuberculosis. Five structures were solved by X-ray crystallographic analysis. These substances are promising antimycobacterial prototypes.


Bioorganic & Medicinal Chemistry | 2012

New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms

Paula F. Carneiro; Samara Braga do Nascimento; Antonio V. Pinto; Maria do Carmo F. R. Pinto; Guilherme C. Lechuga; Dilvani O. Santos; Helvécio M. dos Santos Júnior; Jackson A. L. C. Resende; Saulo C. Bourguignon; Vitor F. Ferreira

New oxirane derivatives were synthesized using six naphthoquinones as the starting materials. Our biological results showed that these oxiranes acted as trypanocidal agents against Trypanosoma cruzi with minimal cytotoxicity in the VERO cell line compared to naphthoquinones. In particular, oxirane derivative 14 showed low cytotoxicity in a mammalian cell line and exhibited better activity against epimastigote forms of T.cruzi than the current drug used to treat Chagas disease, benznidazole.


European Journal of Medicinal Chemistry | 2011

Quinonoid and phenazine compounds: Synthesis and evaluation against H37Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis

Paula F. Carneiro; Maria do Carmo F. R. Pinto; Tatiane S. Coelho; Bruno C. Cavalcanti; Cláudia Pessoa; Carlos A. de Simone; Isabelle K.C. Nunes; Nathália Martins de Oliveira; Renata G. de Almeida; Antonio V. Pinto; Kelly C. G. de Moura; Pedro Eduardo Almeida da Silva; Eufrânio N. da Silva Júnior

Several quinonoid and phenazine compounds were synthesized in moderate to high yields and showed activity against H(37)Rv, rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis. The cytotoxity of the compounds were evaluated against human peripheral blood mononuclear cells (PBMC) and these substances emerge as promising antitubercular prototypes.


Experimental Parasitology | 2014

Evidences for leishmanicidal activity of the naphthoquinone derivative epoxy-α-lapachone

Franklin Souza-Silva; Samara Braga do Nascimento; Saulo C. Bourguignon; Bernardo Acácio Santini Pereira; Paula F. Carneiro; Wellington Seguis da Silva; Carlos Roberto Alves; Rosa Teixeira de Pinho

In this work, we analyze the leishmanicidal effects of epoxy-α-lapachone on Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis. Promasigotes and amastigotes (inhabiting human macrophages) from both species were assayed to verify the compounds activity over the distinct morphological stages. The incubation with epoxy-α-lapachone led to a significant decrease in the numbers of promastigotes from both species in the cultures, in a dose-and time-dependent fashion. The survival of amastigotes inhabiting human macrophages was also drastically affected by the compound, as shown by the variations in the endocytic index. Our results indicate that the epoxy-α-lapachone has an antiparasitic effect over Leishmania in both morphological stages and may potentially affect a range of species in two distinct subgenera of this parasite.


Antimicrobial Agents and Chemotherapy | 2015

Epoxy-α-lapachone has in vitro and in vivo anti-Leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite.

Franklin Souza-Silva; Saulo C. Bourguignon; Bernardo Acácio Santini Pereira; Luzia Monteiro de Castro Côrtes; Luiz Filipe Gonçalves de Oliveira; Andrea Henriques-Pons; Léa Cysne Finkelstein; Vitor F. Ferreira; Paula F. Carneiro; Rosa Teixeira de Pinho; Ernesto R. Caffarena; Carlos Roberto Alves

ABSTRACT Leishmania (Leishmania) amazonensis is a protozoan that causes infections with a broad spectrum of clinical manifestations. The currently available chemotherapeutic treatments present many problems, such as several adverse side effects and the development of resistant strains. Natural compounds have been investigated as potential antileishmanial agents, and the effects of epoxy-α-lapachone on L. (L.) amazonensis were analyzed in the present study. This compound was able to cause measurable effects on promastigote and amastigote forms of the parasite, affecting plasma membrane organization and leading to death after 3 h of exposure. This compound also had an effect in experimentally infected BALB/c mice, causing reductions in paw lesions 6 weeks after treatment with 0.44 mM epoxy-α-lapachone (mean lesion area, 24.9 ± 2.0 mm2), compared to untreated animals (mean lesion area, 30.8 ± 2.6 mm2) or animals treated with Glucantime (mean lesion area, 28.3 ± 1.5 mm2). In addition, the effects of this compound on the serine proteinase activities of the parasite were evaluated. Serine proteinase-enriched fractions were extracted from both promastigotes and amastigotes and were shown to act on specific serine proteinase substrates and to be sensitive to classic serine proteinase inhibitors (phenylmethylsulfonyl fluoride, aprotinin, and antipain). These fractions were also affected by epoxy-α-lapachone. Furthermore, in silico simulations indicated that epoxy-α-lapachone can bind to oligopeptidase B (OPB) of L. (L.) amazonensis, a serine proteinase, in a manner similar to that of antipain, interacting with an S1 binding site. This evidence suggests that OPB may be a potential target for epoxy-α-lapachone and, as such, may be related to the compounds effects on the parasite.


Revista Do Instituto De Medicina Tropical De Sao Paulo | 2015

ANTHELMINTIC ACTIVITY OF LAPACHOL, β-LAPACHONE AND ITS DERIVATIVES AGAINST Toxocara canis LARVAE

Taís Mata-Santos; Nitza Souto França Pinto; Hílton Antônio Mata-Santos; Kelly Gallan De Moura; Paula F. Carneiro; Tatiane dos Santos Carvalho; Karina Pena Del Rio; Maria do Carmo F. R. Pinto; Lourdes Helena Rodrigues Martins; Juliana Montelli Fenalti; Pedro Eduardo Almeida da Silva; Carlos James Scaini

Anthelmintics used for intestinal helminthiasis treatment are generally effective; however, their effectiveness in tissue parasitosis (i.e. visceral toxocariasis) is moderate. The aim of this study was to evaluate the in vitroactivity of lapachol, β-lapachone and phenazines in relation to the viability of Toxocara canis larvae. A concentration of 2 mg/mL (in duplicate) of the compounds was tested using microculture plates containing Toxocara canis larvae in an RPMI-1640 environment, incubated at 37 °C in 5% CO2 tension for 48 hours. In the 2 mg/mL concentration, four phenazines, lapachol and three of its derivatives presented a larvicide/larvistatic activity of 100%. Then, the minimum larvicide/larvistatic concentration (MLC) test was conducted. The compounds that presented the best results were nor-lapachol (MLC, 1 mg/mL), lapachol (MLC 0.5 mg/mL), β-lapachone, and β-C-allyl-lawsone (MLC, 0.25 mg/mL). The larvae exposed to the compounds, at best MLC with 100% in vitro activity larvicide, were inoculated into healthy BALB/c mice and were not capable of causing infection, confirming the larvicide potential in vitro of these compounds.


Memorias Do Instituto Oswaldo Cruz | 2014

Blood shizonticidal activities of phenazines and naphthoquinoidal compounds against Plasmodium falciparum in vitro and in mice malaria studies

Nicolli Bellotti de Souza; Isabel M de Andrade; Paula F. Carneiro; Guilherme A. M. Jardim; Isadora M.M. de Melo; Eufrânio N. da Silva Júnior; Antoniana U. Krettli

Due to the recent advances of atovaquone, a naphthoquinone, through clinical trials as treatment for malarial infection, 19 quinone derivatives with previously reported structures were also evaluated for blood schizonticide activity against the malaria parasite Plasmodium falciparum. These compounds include 2-hydroxy-3-methylamino naphthoquinones (2-9), lapachol (10), nor-lapachol (11), iso-lapachol (12), phthiocol (13) and phenazines (12-20). Their cytotoxicities were also evaluated against human hepatoma and normal monkey kidney cell lines. Compounds 2 and 5 showed the highest activity against P. falciparum chloroquine-resistant blood-stage parasites (clone W2), indicated by their low inhibitory concentration for 50% (IC50) of parasite growth. The therapeutic potential of the active compounds was evaluated according to the selectivity index, which is a ratio of the cytotoxicity minimum lethal dose which eliminates 50% of cells and the in vitro IC50. Naphthoquinones 2 and 5, with activities similar to the reference antimalarial chloroquine, were also active against malaria in mice and suppressed parasitaemia by more than 60% in contrast to compound 11 which was inactive. Based on their in vitro and in vivo activities, compounds 2 and 5 are considered promising molecules for antimalarial treatment and warrant further study.


Journal of Organic Chemistry | 2016

Insight into and Computational Studies of the Selective Synthesis of 6H-Dibenzo[b,h]xanthenes

Paula F. Carneiro; Maria do Carmo F. R. Pinto; Roberta K. F. Marra; Vinícius R. Campos; Jackson A. L. C. Resende; Maicon Delarmelina; José Walkimar de M. Carneiro; Emerson Silva Lima; Fernando de C. da Silva; Vitor F. Ferreira

Starting from 2-hydroxy-1,4-naphthoquinone (lawsone), we synthesized eight new 6H-dibenzo[b,h]xanthene derivatives selectively under solvent-free conditions. Spectroscopic investigations confirmed that only the isomer 6H-dibenzo[b,h]xanthene was obtained in all eight cases. Computational studies provide a rationalization for the selective appearance of these isomers having as an intermediate an addition product.


Frontiers in Microbiology | 2018

Naphthoquinone Derivatives as Scaffold to Develop New Drugs for Tuberculosis Treatment

Priscila Cristina Bartolomeu Halicki; Laís Andrade Ferreira; Kelly C. G. de Moura; Paula F. Carneiro; Karina Pena Del Rio; Tatiane S. C. Carvalho; Maria do Carmo F. R. Pinto; Pedro Eduardo Almeida da Silva; Daniela Fernandes Ramos

Despite being a curable disease, tuberculosis (TB) remains a public health problem worldwide mainly due to lengthy treatment, as well as its toxic effects, TB/HIV co-infection and the emergence of resistant Mycobacterium tuberculosis strains. These barriers reinforcing the need for development of new antimicrobial agents, that ideally should reduce the time of treatment and be active against susceptible and resistant strains. Quinones are compounds found in natural sources and among them, the naphthoquinones show antifungal, antiparasitic, and antimycobacterial activity. Thus, we evaluated the potential antimycobacterial activity of six 1,4-naphthoquinones derivatives. We determined the minimum inhibitory concentration (MIC) of the compounds against three M. tuberculosis strains: a pan-susceptible H37Rv (ATCC 27294); one mono-resistant to isoniazid (ATCC 35822); and one mono-resistant to rifampicin (ATCC 35838); the cytotoxicity in the J774A.1 (ATCC TIB-67) macrophage lineage; performed in silico analysis about absorption, distribution, metabolism, and excretion (ADME) and docking sites. All evaluated naphthoquinones were active against the three strains with MIC between 206.6 and 12.5 μM, and the compounds with lower MIC values have also showed low cytotoxicity. Moreover, two naphthoquinones derivatives 5 and 6 probably do not exhibit cross resistance with isoniazid and rifampicin, respectively, and regarding ADME analysis, no compound violated the Lipinski’s rule-of-five. Considering the set of findings in this study, we conclude that these naphthoquinones could be promising scaffolds to develop new therapeutic strategies to TB.


Parasitology | 2016

Toxocara canis : anthelmintic activity of quinone derivatives in murine toxocarosis

Taís Mata-Santos; Hílton Antônio Mata-Santos; Paula F. Carneiro; K. C. G. De Moura; Juliana Montelli Fenalti; G. B. Klafke; L. A. X. Cruz; Luciane Régio Martins; Nitza Souto França Pinto; Maria do Carmo F. R. Pinto; Maria Elisabeth Aires Berne; P. E. A. da Silva; Carlos James Scaini

Human toxocarosis is a chronic tissue parasitosis most often caused by Toxocara canis. The seroprevalence can reach up to 50%, especially among children and adolescents. The anthelmintics used in the treatment have moderate efficacy. The aim of this study was to evaluate the in vitro and in vivo anthelmintic activity of quinones and their derivatives against T. canis larvae and the cytotoxicity of the larvicidal compounds. The compounds were evaluated at 1 mg mL(-1) concentration in microculture plates containing third stage larvae in an Roswell Park Memorial Institute (RPMI) 1640 environment, incubated at 37 °C in 5% CO2 tension for 48 h. Five naphthoxiranes were selected for the cytotoxicity analysis. The cell viability evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and lactate dehydrogenase assays using murine peritoneal macrophages isolated from C57BL/6 mice revealed that the naphthoxiranes (1 and 3) were less cytotoxic at a concentration of 0.05 mg mL(-1). The efficacy of naphthoxiranes (1 and 3) was examined in murine toxocarosis also. The anthelmintic activity was examined by evaluating the number of larvae in the brain, carcass, liver, lungs, heart, kidneys and eyes. Compound (3) demonstrated anthelmintic activity similar to that of albendazole by decreasing the number of larvae in the organs of mice and thus could form the basis of the development of a new anthelmintic drug.

Collaboration


Dive into the Paula F. Carneiro's collaboration.

Top Co-Authors

Avatar

Maria do Carmo F. R. Pinto

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Vitor F. Ferreira

Federal Fluminense University

View shared research outputs
Top Co-Authors

Avatar

Kelly C. G. de Moura

Federal University of Rio de Janeiro

View shared research outputs
Top Co-Authors

Avatar

Pedro Eduardo Almeida da Silva

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Saulo C. Bourguignon

Federal Fluminense University

View shared research outputs
Top Co-Authors

Avatar

Eufrânio N. da Silva Júnior

Universidade Federal de Minas Gerais

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tatiane S. Coelho

Universidade Federal do Rio Grande do Sul

View shared research outputs
Top Co-Authors

Avatar

Antonio V. Pinto

Federal University of Rio de Janeiro

View shared research outputs
Researchain Logo
Decentralizing Knowledge